Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Cancer Lett. 2011 Oct 12;315(1):48–58. doi: 10.1016/j.canlet.2011.10.007

Fig. 3.

Fig. 3

Cellular effects of TBG-DMAT in benign and malignant prostate cancer cells. A. Reduced cellular proliferation following treatment with TBG-DMAT. PC3-LN4 and BPH-1 cells grown on tenascin-C/fibronectin or laminin protein matrix, respectively, in 96-well plates were treated with 210 and 105 nM TBG-DMAT. DMSO and TBG-Sugar were used as controls. [3H]-thymidine was added after 72 h, and counts collected at 96 h following drug addition. Results are expressed relative to the controls, with treatments and cell lines used shown below. Error bars indicate SEM (n = 4–6). * indicates significant difference from control (P < 0.05). B. CK2 inhibition by DMAT results in loss of NF-κB p65 phospho-Ser529 phosphorylation. PC3-LN4 cells grown on tenascin-C/fibronectin protein matrix were treated with TBG-DMAT or TBG-Sugar and fixed 48 h later for immunofluorescence analysis. TBG nanocapsules used for treatment are indicated to the left of the panels and the proteins detected and nuclear staining with bisbenzimide above. Magnification, 600×.